HSBC Holdings’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

HSBC Holdings’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-15,571	Closed	-$88K	–	3245
2022 Q4	$88K	Hold	15,571	–	–	﹤0.01%	2924
2022 Q3	$103K	Buy	15,571 +611	+4%	+$3.7K	﹤0.01%	2744
2022 Q2	$64K	Buy	+14,960	New	+$59.2K	﹤0.01%	3108

HSBC Holdings's CNCE Position: Q1 2023 in Review

HSBC Holdings sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2023, closing a stake of 15,571 shares — an estimated $88K sold.

HSBC Holdings first reported a position in CNCE in Q2 2022 and held it in 3 quarters. The position peaked at $103K in Q3 2022. 0 funds tracked by Wall St. Rank hold CNCE as of Q1 2023.

HSBC Holdings reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
HSBC Holdings sold 15,571 Concert Pharmaceuticals, Inc. shares in Q1 2023, an estimated $88K.
HSBC Holdings first reported a position in Concert Pharmaceuticals, Inc. in Q2 2022 and held it in 3 quarters.
HSBC Holdings's Concert Pharmaceuticals, Inc. position peaked at $103K in Q3 2022.
0 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2023.

Based on HSBC Holdings's 13F filing for Q1 2023, filed 15 May 2023.